A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer. READ MORE
British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.
Researchers compared intensity-modulated radiation therapy versus conventional radiation therapy by evaluating acute toxicities in the GI and GU systems.
Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.
A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer.
Patients with ovarian cancer who are responsive to platinum-based chemotherapy may experience more than double an increase in PFS with a specific maintenance therapy, regardless of their disease characterization.
Administration of a PARP inhibitor to patients with recurrent ovarian cancer after an initial response to platinum-based chemotherapy helps maintain quality of life during treatment.
Less than 20% of patients with a history of ovarian cancer meeting NCCN guidelines have undergone genetic testing or have discussed testing with their health care providers.
Research in Review
High-grade serous ovarian cancer can be categorized in five molecular subtypes associated with survival and surgical outcomes.
New research questions the value of risk-reducing mastectomy within five years of ovarian cancer diagnosis in patients with BRCA mutations.
A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment.
Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival and overall survival than those without the antigen.
The American College of Obstetricians and Gynecologists has recently updated its clinical guidelines for the management of hereditary breast and ovarian cancer syndrome.